Skip to product information
1 of 1

Invivo anti-Human CD279/PDCD1/PD1 Recombinant mAb (D12)

Invivo anti-Human CD279/PDCD1/PD1 Recombinant mAb (D12)

Catalog Number: S0B7117 Application: ELISA, in vivo neutralization Reactivity: Hu Conjugation: Unconjugated Brand: Starter
Price:
Regular price $175 USD
Regular price Sale price $175 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Human
Antigen CD279 (PD-1)
Synonyms Programmed cell death protein 1; Protein PD-1; hPD-1
Location Cell membrane
Accession Q15116
Clone Number D12
Antibody Type Recombinant mAb
Isotype Human IgG1, κ
Isotype Control S0B1261
Application ELISA, in vivo neutralization
Reactivity Hu
Purification Protein A
Concentration 5 mg/ml
Purity >95% (Determined by SDS-PAGE)
Endotoxin <1EU/mg
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4, containing no preservative

Stability & Storage

2 to 8 °C for 2 weeks under sterile conditions;
-20 °C for 3 months under sterile conditions;
-80 °C for 24 months under sterile conditions.
Please avoid repeated freeze-thaw cycles.

Background

Programmed cell death protein 1 (PD-1), also known as CD279, is a type I transmembrane protein belonging to the CD28 immunoglobulin superfamily. It is encoded by the Pdcd1 gene and consists of 288 amino acids, including an extracellular IgV-like domain, a transmembrane region, and a cytoplasmic tail. PD-1 is expressed on activated T cells, B cells, macrophages, dendritic cells, and natural killer cells. Its cytoplasmic domain contains two tyrosine residues that form an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM), which play key roles in inhibiting T cell receptor signaling. PD-1 interacts with its ligands PD-L1 and PD-L2 to negatively regulate immune responses, contributing to peripheral tolerance and preventing autoimmune diseases. However, this inhibitory function can also suppress anti-tumor immunity, making PD-1 a promising target for cancer immunotherapy.

Picture

Western Blot

WB result of Invivo anti-Human CD279/PDCD1/PD1 Recombinant mAb (D12)
Primary antibody: Invivo anti-Human CD279/PDCD1/PD1 Recombinant mAb (D12) at 1/1000 dilution
Lane 1: PD-1 His Tag Protein, Human 1ug
Secondary antibody: Goat Anti- Human IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 31 kDa
Observed MW: 33 kDa
This blot was developed with high sensitivity substrate